SYNDROME DE GUILLAIN-BARRE ET COVID-19 : A PROPOS D’UN CAS RARISSIME OBSERVE AU CENTRE MEDICAL CANADIEN DIAMANT DE LUBUMBASHI EN RD CONGO GUILLAIN-BARRÉ SYNDROME AND COVID-19: ABOUT AN EXTREMELY RARE CASE OBSERVED AT THE CANADIAN DIAMOND MEDICAL CENTER IN LUBUMBASHI IN DR CONGO
Main Article Content
Abstract
Le syndrome de Guillain-Barré (SGB) résulte d’une réponse immunitaire à une agression le plus souvent virale. Le diagnostic repose sur des critères cliniques, sur les modifications du liquide céphalo-rachidien et sur les anomalies électrophysiologiques. Ce syndrome de Guillain barré peut être associé à la Covid-19. Les immunoglobulines administrées précocement favorisent une récupération de la fonction motrice. Nous vous rapportons une observation d’un patient de 54 ans qui était admis au centre médical diamant de Lubumbashi (CMDL) pour une pneumopathie interstitielle à Covid-19 et pris en charge avec une nette amélioration, mais qui après trois semaines de sa sortie de l’hôpital a présenté un syndrome de Guillain Barré traité aux immunoglobulines avec une bonne récupération motrice.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Author(s) and co-author(s) jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere. Author(s) agree to the terms that the IJRDO Journal will have the full right to remove the published article on any misconduct found in the published article.
References
[2] Caress, J. B., Castoro, R. J., Simmons, Z., Scelsa, S. N., Lewis, R. A., Ahlawat, A., & Narayanaswami, P. COVID‐19–associated Guillain‐Barré syndrome: The early pandemic experience. Muscle & nerve. 2020 ; 62(4), 485-491.
[3] Alberti, P., Beretta, S., Piatti, M., Karantzoulis, A., Piatti, M. L., Santoro, P.et al. Guillain-Barré syndrome related to COVID-19 infection. Neurology- Neuroimmunology Neuroinflammation 2020 ; 7(4).2
[4] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–1069
[5] Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020;92:552–555
[6] Jean-Claude Raphaël Le traitement actuel du syndrome de Guillain-Barré. Bull. Acad. Natle Méd.2004 ; 188(1):87-95
[7] Ch. Verboon, AY. Doets Current treatment practice of Guillain-Barré Syndrome . Neurology July 2, 2019. 93,1.
[8] Wakerley BR, Yuki N. Mimics and chameleons in Guillain-Barré and Miller Fisher syndromes. Pract Neurol 2015; 15: 90–99.
[9] Basse, A. M., Boubacar, S., Sow, A. D., Diagne, N. S., Diop, M. S., Gaye, N. M., et al. Epidemiology of Acute Polyradiculoneuritis at Fann Department of Neurology Dakar, Senegal.
[10] Zhao H, Shen D, Zhou H, Liu J, Chen S Guillain–Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 2020 ; 19(5):383– 384,
[11] Diaz, P., Mitrofan, A., Martinot, M., & Hautecloque, G. Syndrome de Guillain- Barré et COVID-19 : case report. Médecine et Maladies Infectieuses 2020 ; 50(6), S79–S80.].
[12] Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19:383-384.
[13] Juliao Caamaño DS, Alonso BR. Facial diplegia, a possible atypical variant of Guillain-Barré syndrome as a rare neurological complication of SARS-CoV-2. J Clin Neurosci. 2020;77:230-232
[14] Camdessanche J-P, Morel J, Pozzetto B, Paul S, Tholance Y, BotelhoNevers E. COVID-19 may induce Guillain–Barré syndrome. Rev Neurol (Paris). 2020;176:516-518.
[15] El Otmani H, El Moutawakil B, Rafai M-A, et al. Covid-19 and Guillain-Barré syndrome: more than a coincidence! Rev Neurol (Paris). 2020;176:518-519.
[16] Shunmuga sundaram K, Sarala G, Lakshmi narasimhan R, Balasubramanian S, Krishnamoorthy K Comparative efficacy of ivig and plasma exchange in management of guillain barre syndrome . Indian Journal of Applied Research 2019 ; 9(3)
[17] Van der Meché, Schmitz PI A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992 Apr 23;326(17):1123-9 .
[18] Saad K, Mohamad IL, El-Hamed MAA, Tawfeek MSK, Ahmed AE, Baseer KAA, et al. A comparison between plasmapheresis and intravenous immunoglobulin in children with Guillain–Barré syndrome in Upper Egypt. Therapeutic Advances in Neurological Disorders. janv 2016;9(1):3.
[19] Maheshwari A, Sharma RR, Prinja S, Hans R, Modi M, Sharma N, Marwaha N Cost-minimization analysis in the Indian subcontinent for treating Guillain Barre Syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin J Clin Apher. 2018 Dec;33(6):631-63
[20] Gigli GL, Bax F, Marini A, Surcinelli A, Valente M. Guillain–Barré syndrome in the COVID-19 era: just an occasional cluster? J Neurol. https://doi.org/10.1007/s00415-020-09911 -3(Online ahead of print) 2020 .